In the latest chapter of years of legal back-and-forth, attorneys general from 20 states and the District of Columbia have asked a federal appeals court to reverse a decision that an Oregon drug price transparency law is unconstitutional.
The Oregon law, called House Bill 4005, was enacted in 2018 and requires drugmakers to report certain drug pricing information, including justifications for price increases. The pharmaceutical industry’s DC-based trade organization PhRMA challenged the law in Oregon federal court in 2019, and a judge earlier this year sided with plaintiffs’ arguments that certain aspects violate the First Amendment and could violate the Fifth Amendment.
The case now rests with the Ninth Circuit Court of Appeals, and attorneys general are concerned the lower court’s ruling could threaten similar drug price transparency laws in other states.
“Price transparency laws like HB 4005 help states identify drugs causing affordability challenges to…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
